EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Oncological Outcomes and Prognostic Factors of Platinum‐Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum‐Based Chemotherapy Alone: A Propensity Score–Matched Analysis in a Real‐World Population

Yuto Matsushita iD, Yuki Kita iD, Shoichioro Mukai, Akira Joraku, Ikuo Kobayashi, Kei Daizumoto, Tomoyasu Sano, Shotaro Nakanishi iD, Jun Watanabe, Shingo Hatakeyama iD, Akihiro Goriki, Tatsuya Hazama und 9 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70584 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yuto Matsushita und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Avelumab maintenance therapy following platinum‐based chemotherapy is recommended as an alternative treatment in patients with locally advanced or metastatic urothelial carcinoma; however, real‐world data are limited, and no predictive system has been established to identify suitable candidates for avelumab at the initiation of chemotherapy.

Methods

This retrospective study analyzed 324 patients with locally advanced or metastatic urothelial carcinoma who received platinum‐based chemotherapy. Patients were divided into three groups: 130 who received avelumab (avelumab group), 58 who did not experience disease progression on chemotherapy within 4 cycles but did not receive avelumab (PBC‐only group), and 136 who experienced disease progression on chemotherapy within 4 cycles (PBC‐PD group). Oncological outcomes were compared among the groups, and a system for predicting the maintained response to chemotherapy for 4 or more cycles was explored.

Results

The avelumab group had significantly longer overall survival than the other two groups. After propensity score matching, overall survival was significantly longer in the avelumab group than in the PBC‐only group. Lymph node‐only metastasis and a low neutrophil‐to‐lymphocyte ratio were identified as predictive factors for maintaining response to chemotherapy. Among patients with these two factors (favorable group), 81.1% maintained a response, and those who received avelumab maintenance therapy showed that the median overall survival was 33.4 months from initiation of chemotherapy.

Conclusions

The survival benefit of avelumab following chemotherapy compared to chemotherapy alone was confirmed. In the favorable group, avelumab following chemotherapy may be a valuable option if they are ineligible or unwilling to receive the preferred regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Transitional CellAntineoplastic Combined Chemotherapy ProtocolsUrinary Bladder NeoplasmsHumansRetrospective StudiesFemaleMalePropensity ScoreMaintenance ChemotherapyPrognosisAgedMiddle AgedDisease ProgressionTreatment OutcomeCisplatinAntineoplastic Agents, ImmunologicalLymphatic Metastasis

Stichwörter der Autor:innen

avelumab maintenance therapyplatinum‐based chemotherapypredictive systempropensity score matchingurothelial carcinoma

Substanzen

avelumabAntibodies, Monoclonal, HumanizedCisplatinAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan.
  • Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Urology, University of Miyazaki, Miyazaki, Japan.
  • Department of Urology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan.
  • Department of Urology, Aichi Medical University, Nagakute, Aichi, Japan.
  • Department of Urology, Tokushima University, Graduate School of Biomedical Sciences, Tokushima, Japan.

ORCID-Profile: Yuto Matsushita, Yuki Kita, Shotaro Nakanishi, Shingo Hatakeyama, Keiichiro Mori, Hiroshi Kitamura, Takahiro Kimura, Yoshiyuki Matsui, Makito Miyake, Takashi Kobayashi, Teruo Inamoto

Zitieren

APA

Matsushita, Y., Kita, Y., Mukai, S., Joraku, A., Kobayashi, I., Daizumoto, K., Sano, T., Nakanishi, S., Watanabe, J., Hatakeyama, S., Goriki, A., Hazama, T., Nishiyama, N., Mori, K., Kitamura, H., Kimura, T., Matsui, Y., Miyake, M., Kobayashi, T., …, & Japanese Urological Oncology Group (2026). Oncological Outcomes and Prognostic Factors of Platinum‐Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum‐Based Chemotherapy Alone: A Propensity Score–Matched Analysis in a Real‐World Population. International Journal of Urology. https://doi.org/10.1111/iju.70584

Vancouver

Matsushita Y, Kita Y, Mukai S, Joraku A, Kobayashi I, Daizumoto K, et al. Oncological Outcomes and Prognostic Factors of Platinum‐Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum‐Based Chemotherapy Alone: A Propensity Score–Matched Analysis in a Real‐World Population. International Journal of Urology. 2026. doi:10.1111/iju.70584

BibTeX
@article{Matsushita2026,
  author = {Matsushita, Yuto and Kita, Yuki and Mukai, Shoichioro and Joraku, Akira and Kobayashi, Ikuo and Daizumoto, Kei and Sano, Tomoyasu and Nakanishi, Shotaro and Watanabe, Jun and Hatakeyama, Shingo and Goriki, Akihiro and Hazama, Tatsuya and Nishiyama, Naotaka and Mori, Keiichiro and Kitamura, Hiroshi and Kimura, Takahiro and Matsui, Yoshiyuki and Miyake, Makito and Kobayashi, Takashi and Inamoto, Teruo and Japanese Urological Oncology Group, Japanese Urological Oncology Group},
  title = {Oncological Outcomes and Prognostic Factors of Platinum‐Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum‐Based Chemotherapy Alone: A Propensity Score–Matched Analysis in a Real‐World Population},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70584}
}
Kostenlos starten →